Cite
HARVARD Citation
Lenti, M. et al. (n.d.). P352 A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II. Journal of Crohn's and colitis. pp. S372-S373. [Online].